Clinical Applications Beyond Oncology
While most commonly associated with cancer treatment, ubiquitin proteasome drugs are also being explored for other diseases. Conditions involving immune dysregulation and chronic inflammation may benefit from controlled proteasome modulation.
Proteasome inhibition can reduce the production of inflammatory mediators by affecting immune cell signaling pathways. This opens possibilities for treating autoimmune and inflammatory disorders.
Careful dosing and selectivity are essential to avoid excessive immune suppression. Ongoing research focuses on fine-tuning drug action for non-cancer applications.
This expanding scope highlights the versatility of ubiquitin proteasome–based therapies.
1 View